Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer’s Disease
Condition(s):Alzheimer’s DiseaseLast Updated:July 11, 2014Completed
Hide Studies Not Open or Pending
Condition(s):Alzheimer’s DiseaseLast Updated:July 11, 2014Completed
Condition(s):Autistic DisorderLast Updated:October 5, 2017Completed
Condition(s):Brain Tumor; Brain Cancer; Cns Cancer; Cognitive DysfunctionLast Updated:January 14, 2016Completed
Condition(s):Cognitive Impairment; Alzheimer DiseaseLast Updated:January 22, 2020Completed
Condition(s):Alzheimer’s DiseaseLast Updated:March 13, 2014Terminated
Condition(s):HealthyLast Updated:June 5, 2017Completed
Condition(s):Alzheimer’s Disease; DementiaLast Updated:February 14, 2011Completed
Condition(s):HealthyLast Updated:July 20, 2012Completed
Condition(s):HealthyLast Updated:July 10, 2012Completed
Condition(s):Osteoarthritis; Femoral Head Necrosis; Rheumatoid ArthritisLast Updated:January 30, 2020Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.